DOCSLIB.ORG

Immunome, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunome, Inc Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics Immunome, Inc. 665 Stockton Drive, Suite 300 March 14, 2021 Exton, PA 19341 610.321.3700 www.immunome.com Copyright © 2021 Immunome, Inc. All rights reserved. Forward Looking Statements This presentation and any accompanying oral commentary contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than those of historical fact in this presentation and accompanying oral commentary are forward-looking statements. Forward-looking statements may be identified by terminology such as “believe,” “anticipate,” “plan,” “may,” “intend,” “will,” “should,” “expect,” “estimate,” “potential” and “continue” and similar expressions, including the negative of these words, but not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our financial position, strategy, business plans; expectations regarding the timing, progress and achievement of our research and development activities, preclinical studies, any clinical trials and regulatory filings and submissions; our ability to secure and execute on partnerships and collaborations; our expectations regarding the activity and therapeutic potential of our current and future product candidates; our achievement of corporate milestones and the implementation of our business model; and the adequacy of our financial resources to support our operations. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions applicable to Immunome and our industry in general that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with our ability to execute on our strategy, including with respect to the timing of our R&D efforts, regulatory filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by us; our ability to finance our operations; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in our final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in our filings and reports with the SEC. These risks, uncertainties and other factors may cause our actual results to differ materially and adversely from what is contained in (or may be implied from) any forward-looking statements. We operate in a quickly evolving industry and it is not possible to predict all risks and uncertainties. Forward-looking statements speak as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind. Immunome, Inc. | Page 2 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Harness the Power of the Most Educated Components of the Human Overview Immune System • Rapid and unbiased interrogation of human memory B cells to identify novel targets and antibodies directed at them Proprietary • Output has potential to advance 1-2 candidates into IND-enabling studies per year Discovery Engine • Broad applicability across therapeutic areas allows for partnering opportunities • First-in-class fully human antibody targeting IL-38 protein • IND filing anticipated in 2H 2021 Oncology • Growing portfolio of over 50 novel antibody-target pairs for additional therapeutic candidates (IMM-ONC-01) • COVID-19 Multi-Antibody Cocktail targeting SARS-CoV-2 • IND filing anticipated in 1H 2021 Infectious Diseases • $13.3M contract from U.S. Department of Defense to fund IMM-BCP-01 research and development (IMM-BCP-01) • Rapid B cell interrogation potentially enables rapid response to future infectious disease threats Immunome, Inc. | Page 3 Copyright © 2021 Immunome, Inc. All rights reserved. The Power of Immunome’s Discovery Engine Sees Disease Through Memory B Cells the Lens of the Human Memory B Cell Memory B cells are the most educated component of the immune response • Memory B cells remember specific antigens and allow for a rapid antibody response1 • The antibodies that these cells produce are a primary component of the body’s response to a number of diseases: In cancer, the presence of memory B cells in tumors is associated with favorable outcomes in response to I/O therapy2-4 In infectious disease, these cells produce the high affinity antibodies that are responsible for fighting disease 1. B Cell Localization and Migration in Health and Disease, Anja E. Hauser, Uta E. Höpken, in Molecular Biology of B Cells (Second Edition), 2015 2. Helmink et al Nature 577, 549-555; 2020 Immunome, Inc. | Page 4 3. Petiprezet al Nature 577, 556-560; 2020 4. Cabrita et al Nature 577 ,561-565; 2020 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Unbiased Interrogation of Memory B Cells Yields Discovery Engine a Deep and Diverse Set of Potential Therapies Patient Sampling Ongoing access to new and diverse patient memory B cells to feed the engine Immunome Discovery Engine Differentiators Patient Response Capture memory B cells from • Primary human memory B cells immortalized as stable hybridomas - cancer or infectious disease patients thousands of hybridomas per patient Antibody Screening • High-throughput screening - 20,000 antibodies per array Deep, multiplexed interrogation of patient memory B cell responses • Deep interrogation of patient response to generate “hits,” high conversion rate from hits to targets Antibody Validation Definitive target identification and • Directly isolates potential therapeutic antibodies for use characterization of antibody / target interactions in oncology and infectious diseases Discovery Engine Output Unique therapeutic antibody / antigen target pairs Immunome, Inc. | Page 5 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Pipeline & Anticipated Milestones Product Candidate Oncology Target Discovery Preclinical Next Milestone Description Anticipate IND IMM-ONC-01 IL-38 I/O, Novel Checkpoint filing 2H 2021 Product Candidate Anti-infectives Target Discovery Preclinical Next Milestone Description Multiple Anticipate IND IMM-BCP-01 SARS-CoV-2 Antibody cocktail filing 1H 2021 proteins Immunome, Inc. | Page 6 Copyright © 2021 Immunome, Inc. All rights reserved. Oncology Copyright © 2021 Immunome, Inc. All rights reserved. Untapped Potential Current Therapies are Based on Limited Understanding of the in Immuno-Oncology Diversity and Complexity of Human Tumors T cell targeted immuno-oncology approaches have redefined the way we treat cancer However, large number of patients cannot be treated using T cell-targeted approaches Tumors subvert immunity through multiple mechanisms, often simultaneously1 T cell compartment is only one component of a complex immune response to tumors B cells offers untapped biology and a new approach to advancing a novel wave of targets and therapies 1. Bonaventure et al 2019 Front Immunol doi: 10.3389/fimmu.2019.00168 Immunome, Inc. | Page 8 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome’s Memory B Cell Interrogation Reveals Target “Clusters” Discovery & Output Target Cluster 1 Target IMM20059 Cluster 4 Provides critical insights into cancer biology such as: IMM20065 13 22 • Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment1-2 • Novel immune checkpoints that serve as functional, Target Target tumor-derived inhibitors of immunity Cluster 2 10 Cluster 2 5 A Highly Productive Platform; Outputs To Date: 300,000 hybridomas | 1,300 hits 2 22 3 Target 50+ antibody / antigen pairs Cluster 3 Target Cluster 6 IMM20091 IMM20130 1. Adv Clin Chem. 2016;74:103-41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943-019-1074-3 Immunome, Inc. | Page 9 3. Including some commercially-validated targets such as ERBB2 Copyright © 2021 Immunome, Inc. All rights reserved. IL-38: A Novel IL-38 Appears to Dampen Anti-Tumor Immunity Oncology Target Typical Inflammatory Anti-tumor Response Blocking IL-38 is expected to boost anti-tumor immunity • IL-38 is an IL-1 cytokine family member, but
Load more

Recommended publications
  • Phylogenetic Analysis of the Human Antibody Repertoire Reveals Quantitative Signatures of Immune Senescence and Aging
    Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging Charles F. A. de Bourcya, Cesar J. Lopez Angelb, Christopher Vollmersc,1, Cornelia L. Dekkerd, Mark M. Davisb,e,f, and Stephen R. Quakea,c,g,2 aDepartment of Applied Physics, Stanford University, Stanford, CA 94305; bDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305; cDepartment of Bioengineering, Stanford University, Stanford, CA 94305; dDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305; eInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305; fHoward Hughes Medical Institute, Chevy Chase, MD 20815; and gChan Zuckerberg Biohub, San Francisco, CA 94158 Contributed by Stephen R. Quake, December 15, 2016 (sent for review November 4, 2016; reviewed by Nir Hacohen and Rob Knight) The elderly have reduced humoral immunity, as manifested by hypervariable complementarity-determining region 3 (CDR3) in increased susceptibility to infections and impaired vaccine re- Ig heavy-chain (IGH) transcripts (8, 9). sponses. To investigate the effects of aging on B-cell receptor Elderly individuals’ B-cell repertoires have been reported to (BCR) repertoire evolution during an immunological challenge, we exhibit restricted clonal diversity, oligoclonal character, increased used a phylogenetic distance metric to analyze Ig heavy-chain baseline mutation levels, and persistent clonal expansions in pre- transcript sequences in both young and elderly individuals before vious studies of IGH sequence diversity (8, 10). However, previous and after influenza vaccination. We determined that BCR reper- work was limited by small numbers of elderly individuals analyzed toires become increasingly specialized over a span of decades, but (8), did not analyze in detail the composition of the oligoclonal less plastic.
    [Show full text]
  • Efficiency of the Immunome Protein Interaction Network Increases During Evolution Csaba Ortutay*1 and Mauno Vihinen1,2
    Immunome Research BioMed Central Research Open Access Efficiency of the immunome protein interaction network increases during evolution Csaba Ortutay*1 and Mauno Vihinen1,2 Address: 1Institute of Medical Technology, FI-33014 University of Tampere, Finland and 2Tampere University Hospital, FI-33520 Tampere, Finland Email: Csaba Ortutay* - [email protected]; Mauno Vihinen - [email protected] * Corresponding author Published: 22 April 2008 Received: 23 January 2008 Accepted: 22 April 2008 Immunome Research 2008, 4:4 doi:10.1186/1745-7580-4-4 This article is available from: http://www.immunome-research.com/content/4/1/4 © 2008 Ortutay and Vihinen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Details of the mechanisms and selection pressures that shape the emergence and development of complex biological systems, such as the human immune system, are poorly understood. A recent definition of a reference set of proteins essential for the human immunome, combined with information about protein interaction networks for these proteins, facilitates evolutionary study of this biological machinery. Results: Here, we present a detailed study of the development of the immunome protein interaction network during eight evolutionary steps from Bilateria ancestors to human. New nodes show preferential attachment to high degree proteins. The efficiency of the immunome protein interaction network increases during the evolutionary steps, whereas the vulnerability of the network decreases. Conclusion: Our results shed light on selective forces acting on the emergence of biological networks.
    [Show full text]
  • Immunome-Derived Epitope-Driven Vaccines (ID-EDV)
    Available online at www.sciencedirect.com Procedia in Vaccinology 1 (2009) 15–22 2nd Vaccine Global Congress, Boston 2008 Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice Lenny Moisea,b, Matt Arditoa, Joe Desrosiersa, Jill Schriewerc, Mark Bullerd, Sharon E. Freyd, Stephen H. Gregoryb,e, Steven F. Mossb,d, Jinhee Leee, Hardy Kornfeld e, Bill Martina, Anne S. De Groota,b,c,* * aEpiVax, 146 Clifford Street, Providence, RI 02903, USA bAlpert Medical School, Brown University, Providence, RI 02903, USA cInstitute for Immunology and Informatics, University of Rhode Island, 80 Washington Street, Providence, RI 02903, USA d Saint Louis University, St. Louis, MO 63104, USA eLifespan, Rhode Island Hospital, Providence RI, 02903, USA fUniversity of Massachusetts Medical Center, Worcester, MA 01655, USA Abstract While whole killed, whole protein, or live attenuated vaccines were the standard bearers for protective vaccines in the last century, there are concerns about their safety. New vaccine design techniques are contributing to an emphasis on vaccines developed using the minimum essential subset of T- and B-cell epitopes that comprise the “immunome.” We have used bioinformatics sequence analysis tools, epitope-mapping tools, microarrays and high- throughput immunology assays to identify the minimal essential vaccine components for smallpox, tularemia, Helicobacter pylori and tuberculosis vaccines. As will be described in this review, this approach has resulted in the development of four immunome-derived epitope-driven vaccines (ID-EDV); three of these proved protective against viral or bacterial challenge. Protective efficacies of 100% (vaccinia), 90% (H. pylori), and 57% (tularemia) were achieved in HLA-transgenic (humanized) mouse models and the p27 knockout mouse (for H.
    [Show full text]
  • Citrullinated Protein Antibodies in Rheumatoid Arthritis
    ARTHRITIS & RHEUMATOLOGY Vol. 70, No. 12, December 2018, pp 1946–1958 DOI 10.1002/art.40587 © 2018, American College of Rheumatology Affinity Maturation Drives Epitope Spreading and Generation of Proinflammatory Anti–Citrullinated Protein Antibodies in Rheumatoid Arthritis Serra E. Elliott, Sarah Kongpachith, Nithya Lingampalli, Julia Z. Adamska, Bryan J. Cannon, Rong Mao, Lisa K. Blum, and William H. Robinson Objective. Rheumatoid arthritis (RA) is character- were observed (P < 0.01). Shared complementarity-deter- ized by the presence of anti–citrullinated protein antibod- mining region 3 sequence motifs were identified across ies (ACPAs); nevertheless, the origin, specificity, and subjects. A subset of the plasmablast lineages included functional properties of ACPAs remain poorly under- members derived from later time points with divergent stood. The aim of this study was to characterize the evolu- somatic hypermutations that encoded antibodies that tion of ACPAs by sequencing the plasmablast antibody bind an expanded set of citrullinated antigens. Further- repertoire at serial time points in patients with estab- more, these recombinant, differentially mutated plas- lished RA. mablast antibodies formed immune complexes that Methods. Blood samples were obtained at up to 4 stimulated higher macrophage production of tumor serial time points from 8 individuals with established RA necrosis factor (TNF) compared to antibodies represent- who were positive for ACPAs by the anti–cyclic citrulli- ing earlier time point–derived lineage members that were nated peptide test. CD19+CD3ÀIgDÀCD14ÀCD20À less mutated. CD27+CD38++ plasmablasts were isolated by single-cell Conclusion. These findings demonstrate that sorting and costained with citrullinated peptide established RA is characterized by a persistent IgA tetramers to identify ACPA-expressing plasmablasts.
    [Show full text]
  • Integration of Immunome with Disease Gene Network Reveals Pleiotropy and Novel Drug 2 Repurposing Targets
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.12.874321; this version posted December 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Integration of immunome with disease gene network reveals pleiotropy and novel drug 2 repurposing targets 3 Abhinandan Devaprasad1, Timothy RDJ Radstake1, Aridaman Pandit1* 4 1 Center for Translation Immunology, University Medical Center Utrecht, Utrecht, The 5 Netherlands 6 *Correspondence: Aridaman Pandit: [email protected] 7 8 Abstract 9 Immune system is crucial for the development and progression of immune-mediated and non- 10 immune mediated complex diseases. Studies have shown that multiple complex diseases are 11 associated with several immunologically relevant genes. Despite such growing evidence, the 12 effect of disease associated genes on immune functions has not been well explored. Here, we 13 curated the largest immunome (transcriptome profiles of 40 different immune cells) and 14 integrated it with disease gene networks and drug-gene database, to generate a Disease-gene 15 IMmune cell Expression network (DIME). We used the DIME network to: (1) study 13,510 16 genes and identify disease associated genes and immune cells for >15,000 complex diseases; 17 (2) study pleiotropy between various phenotypically distinct rheumatic and other non- 18 rheumatic diseases; and (3) identify novel targets for drug repurposing and discovery. We 19 implemented DIME as a tool (https://bitbucket.org/systemsimmunology/dime) that allows 20 users to explore disease-immune-cell associations and disease drug networks to pave way for 21 future (pre-) clinical research.
    [Show full text]
  • Immunome Discovery Engine Simultaneously Identifies Antibodies and Their Antigen Targets by Interrogating the Patient’S Memory B Cells in an Unbiased Manner
    Developing Antibody‐Based Therapeutics by Unlocking the Human Memory B Cell Response Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 October 26, 2020 610.321.3700 www.immunome.com Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward-looking terminology such as “believes,” “anticipates,” “plans,” “may,” “intends,” “will,” “should,” “expects,” and similar expressions to identify forward-looking statements. Further, forward-looking statements include, but are not limited to, statements regarding the Company’s financial position, strategy, business plans, expectations regarding the timing and achievement of its product candidate development activities and ongoing and planned preclinical studies and clinical trials, plans and expectations for future operations and research and development initiatives. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These forward-looking statements involve risks and uncertainties, including regarding the Company’s expectation that it will incur net losses for the foreseeable future, and that it may never be profitable; its need for additional funding; the timing and success of preclinical studies and clinical trials it conducts; the ability to obtain and maintain regulatory approval of its product candidates; the ability to commercialize its product candidates; its ability to compete in the marketplace; developments relating to the COVID-19 pandemic; its ability to obtain and maintain intellectual property protection for its product candidates; and its ability to manage growth. These or other risks or uncertainties may cause the Company’s actual results to differ materially from any forward-looking statements.
    [Show full text]
  • An Integrated Genomic and Immunoinformatic Approach to H
    University of Rhode Island DigitalCommons@URI Institute for Immunology and Informatics Faculty Institute for Immunology and Informatics (iCubed) Publications 2011 An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design Matthew Ardito Joanna Fueyo See next page for additional authors Creative Commons License This work is licensed under a Creative Commons Attribution 3.0 License. Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs Terms of Use All rights reserved under copyright. Citation/Publisher Attribution Ardito, M., Fueyo, J., Tassone, R., Terry, F., DaSilva, K., Zhang, S., Martin, W., De Groot, A. S., Moss, S. F., & Moise, L. (2011). An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design. Immunome Research, 7(2). Available at: http://dx.doi.org/10.4172/1745-7580.1000049 This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. Authors Matthew Ardito, Joanna Fueyo, Ryan Tassone, Frances Terry, Kristin DaSilva, Songhua Zhang, William Martin, Anne S. De Groot, Steven F. Moss, and Leonard Moise This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/32 Ardito et al. Immunome Research 2011, 7:2:1 http://www.immunome-research.net/ RESEARCH Open Access An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design Matthew Ardito1, Joanna Fueyo2¶, Ryan Tassone1, Frances Terry1, Kristen DaSilva3, Songhua Zhang4, Wil- liam Martin1, Anne S.
    [Show full text]
  • RESEARCH Open Access
    Alamyar et al. Immunome Research 2012, 8:1:2 http://www.immunome-research.net/ RESEARCH Open Access IMGT/HIGHV-QUEST: THE IMGT® WEB PORTAL FOR IMMUNOGLOBULIN (IG) OR ANTIBODY AND T CELL RECEPTOR (TR) ANALYSIS FROM NGS HIGH THROUGHPUT AND DEEP SEQUENCING Eltaf Alamyar 1, Véronique Giudicelli 1, Shuo Li 2, Patrice Duroux 1, Marie-Paule Lefranc1§ ABSTRACT BACKGROUND The number of antigen receptors, immunoglobulins (IG) or antibodies and T cell receptors (TR) of the adap- tive immune response in vertebrates with jaws is almost unlimited (2.1012 per individual in humans). This huge diversity results from complex mechanisms in the synthesis of the variable (V) domains, that include DNA molecular rearrangements of the V, diversity (D) and joining (J) genes, N-diversity at the V-(D)-J junc- tions and, for IG, somatic hypermutations. The specificity of the V domains is conferred by the complemen- tarity determining regions (CDR) and more particularly the CDR3. IMGT®, the international ImMunoGeneT- ics information system®, has developed online tools that provide a detailed and accurate sequence analy- sis of the V domains (IMGT/V-QUEST) and CDR3 (IMGT/JunctionAnalysis), based on IMGT-ONTOLOGY. However online analyses are limited to 50 sequences per batch. The challenge was to provide identical high quality analysis for the huge number of sequences obtained by Next Generation Sequencing (NGS) high throughput and deep sequencing. Results IMGT® has developed IMGT/HighV-QUEST that analyses up to 150,000 IG or TR V domain sequences per batch and performs statistical analysis on the results of up to 450,000 sequences.
    [Show full text]
  • A Model of Somatic Hypermutation Targeting in Mice Based on High-Throughput Ig Sequencing Data
    A Model of Somatic Hypermutation Targeting in Mice Based on High-Throughput Ig Sequencing Data This information is current as Ang Cui, Roberto Di Niro, Jason A. Vander Heiden, Adrian of October 1, 2021. W. Briggs, Kris Adams, Tamara Gilbert, Kevin C. O'Connor, Francois Vigneault, Mark J. Shlomchik and Steven H. Kleinstein J Immunol published online 5 October 2016 http://www.jimmunol.org/content/early/2016/10/05/jimmun ol.1502263 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/10/05/jimmunol.150226 Material 3.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 1, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 5, 2016, doi:10.4049/jimmunol.1502263 The Journal of Immunology A Model of Somatic Hypermutation Targeting in Mice Based on High-Throughput Immunoglobulin Sequencing Data Ang Cui,* Roberto Di Niro,† Jason A. Vander Heiden,* Adrian W.
    [Show full text]
  • Immunomic Analysis of Human Sarcoma
    Immunomic analysis of human sarcoma Sang-Yull Lee*, Yuichi Obata†, Masahiro Yoshida‡, Elisabeth Stockert*, Barbara Williamson*, Achim A. Jungbluth*, Yao-Tseng Chen*§, Lloyd J. Old*, and Matthew J. Scanlan*¶ *Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; †RIKEN Bioresource Center, RIKEN Tsukuba Institute, 3-1-1 Koyadai Tsukuba 305-0074, Japan; ‡Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan; and §Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021 Contributed by Lloyd J. Old, December 30, 2002 The screening of cDNA expression libraries from human tumors (17) that elicit spontaneous cellular (18) and humoral immune with serum antibody (SEREX) has proven to be a powerful method (19) responses in some cancer patients. Because of their tissue- for identifying the repertoire of tumor antigens recognized by the restricted expression and immunogenicity, CT antigens are immune system of cancer patients, referred to as the cancer potential targets for vaccine-based immunotherapies. In general, immunome. In this regard, cancer͞testis (CT) antigens are of CT antigens are expressed in 20–40% of specimens from a given particular interest because of their immunogenicity and restricted tumor type (18, 20). One exception to this is synovial sarcoma, expression patterns. Synoivial sarcomas are striking with regard to in which 80% of specimens express the CT antigens, NY-ESO-1 CT antigen expression, with >80% of specimens homogeneously (21), and MAGE (22). expressing NY-ESO-1 and MAGE-A3. In the present study, 54 The current study examines the humoral immune response of sarcoma patients were tested for serum antibodies to NY-ESO-1, sarcoma patients to sarcoma and testicular antigens.
    [Show full text]
  • Protein-Based Immunome Wide Association Studies (PIWAS) for the Discovery of Significant Disease-Associated Antigens
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.18.997759; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Protein-based Immunome Wide Association 2 Studies (PIWAS) for the discovery of 3 significant disease-associated antigens 4 Winston A. Haynes1, Kathy Kamath1, Patrick S. Daugherty1, John C. Shon1,* 5 1Serimmune, Inc. Santa BarBara, CA, USA. 6 *Corresponding author: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.18.997759; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 7 Abstract 8 Identification of the antigens associated with antiBodies is vital to understanding immune 9 responses in the context of infection, autoimmunity, and cancer. Discovering antigens at a 10 proteome scale could enable Broader identification of antigens that are responsiBle for 11 generating an immune response or driving a disease state. Although targeted tests for known 12 antigens can Be straightforward, discovering antigens at a proteome scale using protein and 13 peptide arrays is time consuming and expensive. We leverage Serum Epitope Repertoire 14 Analysis (SERA), an assay Based on a random Bacterial display peptide liBrary coupled with NGS, 15 to power the development of Protein-Based Immunome Wide Association Study (PIWAS).
    [Show full text]
  • Immunome Research Biomed Central
    Immunome Research BioMed Central Research Open Access Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site Brett A McKinney*1, Nicole L Kallewaard2, James E Crowe Jr3 and Jens Meiler4 Address: 1Department of Genetics, University of Alabama School of Medicine, 720 20th Street South, Birmingham, 35294, USA, 2Division of Infectious Diseases, Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, 19104 USA, 3Program in Vaccine Sciences, Departments of Microbiology and Immunology and Pediatrics, Vanderbilt University Medical Center, 21st Avenue South and Garland Avenue, Nashville, 37232, USA and 4Center for Structural Biology, Department of Chemistry, Vanderbilt University, 2201 West End Avenue, Nashville, 37232, USA Email: Brett A McKinney* - [email protected]; Nicole L Kallewaard - [email protected]; James E Crowe - [email protected]; Jens Meiler - [email protected] * Corresponding author Published: 18 September 2007 Received: 4 June 2007 Accepted: 18 September 2007 Immunome Research 2007, 3:8 doi:10.1186/1745-7580-3-8 This article is available from: http://www.immunome-research.com/content/3/1/8 © 2007 McKinney et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Understanding the interaction between viral proteins and neutralizing antibodies at atomic resolution is hindered by a lack of experimentally solved complexes. Progress in computational docking has led to the prediction of increasingly high-quality model antibody-antigen complexes.
    [Show full text]